ClinicalTrials.gg
Active, not recruitingNCT07022717Updated Nov 12, 2026

A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk

An interventional study of Brief youth overdose prevention education and Usual standard of care in Overdose, sponsored by Boston Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Health services research

How we know

Updated Nov 12, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Drug Overdose with a site in United States — 17 open to participants now, 28 under way, none of them phase 3. Drug Overdose · United States.

Enrollment
52nd of 58
26 · median 182
Started
2025
with 5 others
No phase
51 of 72
13 open now
Primary completion
2026-11
later than 8 of 27 live
Registered
60th of 72
by date

Among the 72 studies in Drug Overdose with a site in United States, this one is the 52nd largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2025, is one of 51 with no phase, reaches primary completion later than 8 of the 27 other live ones, and was the 60th registered.

Drug Overdose

104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.

Browse Drug Overdose studies →

Open to participants now

17 of the 72 studies in Drug Overdose with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Drug Overdose studies recruiting now, 12 (92%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Drug Overdose with a site in United States, or all of them as a file.
02

Study summary

Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States. Healthcare providers have regular and trusted relationships with youth and have experience in providing public health injury prevention counseling. Youth have different motivations for using drugs, and many who experience fatal overdose do not have a history of opioid use. Primary care pediatric providers regularly provide developmentally appropriate injury prevention counseling for leading causes of pediatric fatal and nonfatal injury such as drowning prevention and firearms safety. However, there are no recommended, evidence-based overdose prevention interventions for youth, including in health care settings, even though research supports pediatricians and youth-serving clinicians providing harm reduction strategies such as naloxone distribution and overdose education. Among adults, overdose prevention education reduces overdose, is cost-effective, and can be learned by laypersons. Content commonly includes awareness of fentanyl in the drug supply, risk reduction (e.g., not using alone, risks of polysubstance use), and how to recognize and respond to an overdose, including the use of naloxone.

This study is a pilot two-arm cluster randomized controlled trial (RCT) of a brief overdose prevention education intervention that will be developed in collaboration with the Community Advisory Board (CAB). The primary outcome of this study is to assess the feasibility and acceptability of the brief youth overdose prevention intervention as measured by provider feasibility and acceptability as well as youth acceptability.

03

Conditions studied

  • Overdose

Browse trials for

Keywords

  • Brief overdose prevention
  • Naloxone
  • Youth patients
  • Health care providers
  • Primary care
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for providers:

  • Physicians and advance practice providers within Pediatric Primary Care and Family Medicine at Boston Medical Center (BMC)
  • ≥ 1 clinic sessions per/week

Exclusion Criteria for providers:

  • None

Inclusion criteria for youth:

  • Ages 13-26
  • Scheduled for a comprehensive physical exam exam (CPE) or follow-up clinical appointment with a provider who is participating in the trial
  • English speaking

Exclusion criteria for youth:

  • Caregivers of youth ages 13-17 unable to provide or are not English speaking
  • Cognitive limitation or intellectual disability that in the opinion of their provider would not
  • Any medical/psychiatric condition that causes acute distress and requires emergency evaluation
  • Under legal custody of the Department of Children and Families (DCF)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Intervention group

    Providers randomized to the intervention group will complete a 45-minute intervention training. The training will occur either in person or via videoconference and include overdose prevention education, the pilot brief overdose prevention education intervention, intervention practice, and how to complete the fidelity checklist to be completed at the end of each visit.

    Behavioral: Brief youth overdose prevention education

  • Active comparator
    Control group

    Providers randomized to the control group will provide usual care to youth during comprehensive physical exams (CPEs) or follow-up clinical appointments.

    Other: Usual standard of care

Interventions

  • BehavioralBrief youth overdose prevention education

    Providers in the intervention group will inform youth participants about: the risk factors for overdose, how to recognize an overdose, and how to respond to an overdose. Providers in the intervention group will also educate youth participants on naloxone use and provide assistance with accessing naloxone

  • OtherUsual standard of care

    Youth participants will be provided usual care by providers in the control group. As part of usual care, providers may educate youth participants on naloxone use and provide assistance with accessing naloxone.

06

What researchers measure

Primary outcomes

  1. Provider feasibility of the brief overdose prevention education intervention

    Providers in the intervention arm will complete a checklist after all comprehensive physical exams (CPEs) or follow-up clinical appointments with youth ages 13 to 26 years. The checklist will assess which components of the intervention the provider was able to deliver during the visit.

    Time frame: 6 months

  2. Provider acceptability of the brief overdose prevention education intervention

    Providers in the intervention group will complete 8 questions based on the Theoretical Framework of Acceptability (TFA) acceptability questionnaire on a 5-point Likert scale. The measure will be collected post-intervention training and after all youth have received the intervention

    Time frame: 6 months

  3. Youth feasibility of the brief overdose prevention education intervention

    Youth in the intervention arm will complete a checklist after their CPEs or follow-up clinical appointments. The checklist will assess which components of the intervention their provider was able to deliver during the visit.

    Time frame: 6 months

Secondary outcomes

  1. Youth knowledge of risk associated with exposure to fentanyl and other emerging drugs

    Assessed using a 4-point Likert scale question adapted from the Monitoring the Future (MTF) survey measuring perceived risk of harm from taking prescription medication that was not prescribed or taking medication other than prescribed.

    Time frame: Baseline, 2 weeks, 6-months

  2. Youth knowledge of strategies to reduce overdose risk

    Assessed using a 4-point Likert scale questions adapted from the Monitoring the Future (MTF) survey measuring perceived risk associated with using more than one substance at a time and using substances while alone. Possible scores range from 1 (no risk) to 4 (great risk), with higher scores indicating greater perceived risk of harm (a better outcome).

    Time frame: Baseline, 2 weeks, 6-months

  3. Youth's ability to recognize an opioid overdose

    Assessed using a question adapted from the Opioid Overdose Knowledge Scale (OOKS) evaluating participants' ability to identify signs of an opioid overdose.

    Time frame: Baseline, 2 weeks, 6-months

  4. Youth's ability to respond to an opioid overdose

    Assessed using a question adapted from the Opioid Overdose Knowledge Scale (OOKS) evaluating participants' knowledge of steps in opioid overdose response.

    Time frame: Baseline, 2 weeks, 6-months

07

Study locations

1 site
  • Boston Medical Center, Pediatric Primary Care & Family Medicine
    Boston, Massachusetts 02118, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.

Of 47 non-industry interventional studies with no phase under Drug Overdose, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 15 months is below that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
22→26
Nov 9, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • Edited≥ 21 clinic sessions per/week
  • EditedScheduled for a comprehensive physical exam exam (CPE) or follow-up clinical appointment with a provider who is participating in the trial
Nov 12, 2026
Interventions
Removed Information about Naloxone
Nov 12, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedFeasibilityProvider feasibility of the brief overdose prevention education interventionTime frame: 6 months
  • EditedYouth acceptabilityfeasibility of the brief overdose prevention education interventionTime frame: 6 months
Nov 12, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedYouth perceptionknowledge of risk associated with exposure to fentanyl and other emerging drugsTime frame: Baseline, 2 weeks, 6-months
  • EditedYouth awarenessknowledge of strategies to reduce overdose riskTime frame: Baseline, 2 weeks, 6-months
  • EditedYouth's ability to recognize an opioid overdoseTime frame: Baseline, 2 weeks, 6-months
  • EditedYouth's ability to respond to an opioid overdoseTime frame: Baseline, 2 weeks, 6-months
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Eligibility 2 criteria edited
    What changed in the criteria
    • Edited≥ 21 clinic sessions per/week
    • EditedScheduled for a comprehensive physical exam exam (CPE) or follow-up clinical appointment with a provider who is participating in the trial
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedFeasibilityProvider feasibility of the brief overdose prevention education interventionTime frame: 6 months
    • EditedYouth acceptabilityfeasibility of the brief overdose prevention education interventionTime frame: 6 months
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedYouth perceptionknowledge of risk associated with exposure to fentanyl and other emerging drugsTime frame: Baseline, 2 weeks, 6-months
    • EditedYouth awarenessknowledge of strategies to reduce overdose riskTime frame: Baseline, 2 weeks, 6-months
    • EditedYouth's ability to recognize an opioid overdoseTime frame: Baseline, 2 weeks, 6-months
    • EditedYouth's ability to respond to an opioid overdoseTime frame: Baseline, 2 weeks, 6-months
    Interventions Removed Information about Naloxone
    + 1 other change: index terms
  2. Nov 9, 2026
    Enrollment 22→26
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07022717
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Aug 25, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Sarah Bagley, MD MSc
principal investigator · Boston Medical Center, Internal Medicine, Addiction Medicine
Amy Yule, MD
principal investigator · Boston Medical Center, Psychiatry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion